keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/29427512/the-use-of-brexpiprazole-amongst-individuals-with-insufficient-outcomes-with-aripiprazole-or-bupropion-a-case-series
#1
Traci Aladeen, Erica Westphal, Yena Lee, Carola Rong, Michelle Rainka, Horacio Capote, Roger S McIntyre
PURPOSE: We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider. DESIGN AND METHODS: Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion. FINDINGS: The majority of individuals in our sample exhibited tolerability of brexpiprazole...
February 10, 2018: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/29427000/tardive-dyskinesia-associated-with-atypical-antipsychotics-prevalence-mechanisms-and-management-strategies
#2
REVIEW
Katharina Stegmayer, Sebastian Walther, Peter van Harten
All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the prevalence and etiology of and management strategies for TD associated with AAPs. TD prevalence rates varied substantially between studies, with an estimated prevalence of around 20% in patients using AAPs...
February 9, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29423659/venous-thromboembolism-during-treatment-with-antipsychotics-a-review-of-current-evidence
#3
REVIEW
Anna K Jönsson, Johan Schill, Hans Olsson, Olav Spigset, Staffan Hägg
This article summarises the current evidence on the risk of venous thromboembolism (VTE) with the use of antipsychotics. An increasing number of observational studies indicate an elevated risk of VTE in antipsychotic drug users. Although the use of certain antipsychotics has been associated with VTE, current data can neither conclusively verify differences in occurrence rates of VTE between first- and second-generation antipsychotics or between individual compounds, nor identify which antipsychotic drugs have the lowest risk of VTE...
February 8, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29409162/antipsychotic-reduction-and-or-cessation-and-antipsychotics-as-specific-treatments-for-tardive-dyskinesia
#4
REVIEW
Hanna Bergman, John Rathbone, Vivek Agarwal, Karla Soares-Weiser
BACKGROUND: Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29395607/a-quantitative-systems-pharmacology-study-on-optimal-scenarios-for-switching-to-paliperidone-palmitate-once-monthly
#5
Hugo Geerts, Athan Spiros, Patrick Roberts, Larry Alphs
Long-acting injectable (LAI) antipsychotic formulations are increasingly used for improving patient compliance and long-term outcomes. Transitioning to LAIs raises questions regarding how optimum efficacy can be rapidly achieved while minimizing potential efficacy and safety concerns related to overlapping plasma levels of prior treatments and the new LAI. Ideally, randomized clinical trials would provide guidance regarding transition algorithms, but the number of studies and sample size required to address relevant questions makes this approach unachievable...
January 25, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29359582/paliperidone-palmitate-three-month-depot-formulation-a-helpful-innovation-with-practical-pitfalls
#6
Judith D Hope, Nicholas A Keks
OBJECTIVE: Paliperidone palmitate is now available as a three-month depot injection. This paper will review the pharmacokinetics, pharmacodynamics, efficacy and tolerability, as well as practical issues and pitfalls for clinicians with this innovative treatment for schizophrenia. CONCLUSION: The three-month depot formulation of paliperidone for the treatment of schizophrenia is not a new compound. The nanocrystalline structure of the three-month formulation is larger and takes longer to disperse than the one-month formulation, hence its extended depot action...
January 1, 2018: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/29356004/training-switching-focus-with-a-mobile-application-by-a-patient-suffering-from-avh-a-case-report
#7
Lucia Visser, Igne Sinkeviciute, Iris E Sommer, Josef J Bless
Auditory verbal hallucinations complicate many psychiatric disorders. Antipsychotic medication is effective in the majority, but a significant minority experiences high burden from resistant hallucinations. Here, we aim to improve executive control, in an attempt to decrease burden from hallucinations. We describe the use of a cognitive trainings app by a young woman with highly resistant hallucinations. With modest training, a significant decrease in the duration of hallucinations was reached. Possibilities of this training technique are discussed...
February 2018: Scandinavian Journal of Psychology
https://www.readbyqxmd.com/read/29324468/switching-antipsychotic-treatment-to-aripiprazole-in-psychotic-patients-with-neuroleptic-induced-tardive-dyskinesia-a-24-week-follow-up-study
#8
Chia-Hsiang Chan, Hung-Yu Chan, Yen-Ching Chen
Aripiprazole is a second-generation antipsychotics, acting as a partial dopamine D2 receptor agonist. Previous studies on aripiprazole for tardive dyskinesia (TD) treatment were limited and inconclusive. This study was aimed to examine the effectiveness of aripiprazole in psychotic patients with a pre-existing TD. This was an open-label 24-week prospective cohort study conducted in a public mental hospital in Northern Taiwan from January 2009 to February 2010.Psychotic patients were cross-titrated of prior antipsychotics with aripiprazole, and the severity of TD was assessed at baseline and at weeks 2, 4, 8, 12, 16, 20, and 24...
January 10, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29278206/a-systematic-review-of-evidence-based-treatment-strategies-for-obsessive-compulsive-disorder-resistant-to-first-line-pharmacotherapy
#9
Umberto Albert, Donatella Marazziti, Gabriele Di Salvo, Francesca Solia, Gianluca Rosso, Giuseppe Maina
BACKGROUND: Serotonin reuptake inhibitors (SRIs) and cognitive-behavioral psychotherapy (CBT) are first-line treatments for obsessive-compulsive disorder (OCD). However, a significant proportion of patients do not respond satisfactorily to first-choice treatments. Several options have been investigated for the management of resistant patients. OBJECTIVE: The aim of the present paper is to systematically review the available literature concerning the strategies for the treatment of resistant adult patients with OCD...
December 22, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/29232310/comparison-of-paliperidone-palmitate-and-risperidone-long-acting-injection-in-schizophrenic-patients-results-from-a-multicenter-retrospective-cohort-study-in-france
#10
Frédéric Limosin, Drifa Belhadi, Denis Comet, Maud Pacou, Sophie Bouju, Kristel Van Impe, Pascal Guillon
PURPOSE/BACKGROUND: The study objective was to compare the impact of being treated by paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) on the length of stay on initial hospitalization, rehospitalization risk, and treatment duration in schizophrenic patients. METHODS: We conducted an observational retrospective cohort study in 43 centers in France, including schizophrenic patients who initiated a treatment by PP or RLAI during initial hospitalization...
February 2018: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29228982/electroconvulsive-therapy-for-manic-state-with-mixed-and-psychotic-features-in-a-teenager-with-bipolar-disorder-and-comorbid-episodic-obsessive-compulsive-disorder-a-case-report
#11
Olof Rask, Klara Suneson, Eva Holmström, Beata Bäckström, Björn Axel Johansson
BACKGROUND: Comorbidity of bipolar disorder and obsessive-compulsive disorder is common in adolescence. Obsessive-compulsive disorder symptoms may be episodic and secondary to alterations in mood, and display specific features. Management of pediatric bipolar disorder-obsessive-compulsive disorder is challenging, as pharmacotherapy of obsessive-compulsive disorder may induce or exacerbate manic episodes and there is limited evidence of treatment efficacy. Electroconvulsive therapy is sparsely used in children and adolescents, but is documented to be a safe and efficacious intervention in adults with bipolar disorder...
December 12, 2017: Journal of Medical Case Reports
https://www.readbyqxmd.com/read/29224570/mapping-the-evidence-on-pharmacological-interventions-for-non-affective-psychosis-in-humanitarian-non-specialised-settings-a-unhcr-clinical-guidance
#12
Giovanni Ostuzzi, Corrado Barbui, Charlotte Hanlon, Sudipto Chatterjee, Julian Eaton, Lynne Jones, Derrick Silove, Peter Ventevogel
BACKGROUND: Populations exposed to humanitarian emergencies are particularly vulnerable to mental health problems, including new onset, relapse and deterioration of psychotic disorders. Inadequate care for this group may lead to human rights abuses and even premature death. The WHO Mental Health Gap Action Programme Intervention Guide (mhGAP-IG), and its adaptation for humanitarian settings (mhGAP-HIG), provides guidance for management of mental health conditions by non-specialised healthcare professionals...
December 11, 2017: BMC Medicine
https://www.readbyqxmd.com/read/29216606/first-and-second-line-pharmacological-treatment-for-delirium-in-general-hospital-setting-retrospective-analysis
#13
Ken Wada, Yukitaka Morita, Takashi Iwamoto, Yoshihiro Mifune, Shinji Nojima
AIM: We examined the first- and second-line pharmacological treatment for delirium to determine which drugs were chosen, how and when second-line drugs were started, and the effectiveness and tolerability of those treatments. METHODS: A retrospective medical chart review was performed for delirium inpatients referred to the Department of Psychiatry, Hiroshima Citizens Hospital, from October 2011 to September 2012. Clinical diagnoses were based on ICD-10. We compared the baseline severity of delirium, duration needed for improvement, and rescue with antipsychotics between subjects given only first-line drugs and those switched to second-line drugs...
December 4, 2017: Asian Journal of Psychiatry
https://www.readbyqxmd.com/read/29200857/reversal-of-olanzapine-induced-weight-gain-in-a-patient-with-schizophrenia-by-switching-to-asenapine-a-case-report
#14
Kosuke Okazaki, Kazuhiko Yamamuro, Toshifumi Kishimoto
Aims: Antipsychotics are effective for treating schizophrenia, but atypical antipsychotics can cause several adverse side effects including weight gain, hyperprolactinemia, and extrapyramidal symptoms. Moreover, weight gain increases the risk of metabolic diseases. Methods: We treated a case of olanzapine-induced weight gain in a 41-year-old man with schizophrenia by switching his medication from olanzapine to asenapine. Results: The weight gain improved after switching the medication, from 80...
2017: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29195836/is-the-risk-of-antipsychotic-polypharmacy-discontinuation-dependent-on-the-agents-used
#15
Robert J Constantine, Ross Andel, Marie McPherson, Rajiv Tandon
This study assesses the risks and benefits of switching from two to one antipsychotic among participants on two non-clozapine oral antipsychotics, and among those on combinations involving either clozapine or an injectable antipsychotic. Ninety adult participants with schizophrenia or schizoaffective disorder were assigned to stay on polypharmacy or to switch to monotherapy. Half of these participants were receiving combinations of non-clozapine oral antipsychotics and half were receiving combinations involving either clozapine or an injectable antipsychotic...
October 7, 2017: Psychiatry Research
https://www.readbyqxmd.com/read/29138607/evaluation-of-sleep-profile-in-schizophrenia-patients-treated-with-extended-release-paliperidone-an-open-label-prospective-study-in-southeast-asia
#16
Ronnachai Kongsakon, Nuntika Thavichachart, Ka Fai Chung, Leslie Lim, Beverly Azucena, Elizabeth Rondain, Benson Go, Fe Costales, Osot Nerapusee
Objective: To evaluate the effect of 6 months of treatment with paliperidone extended-release (ER) tablets on the sleep profile of patients with schizophrenia. Methods: A total of 984 patients meeting the The Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria for schizophrenia who switched their antipsychotic to paliperidone ER were recruited from 61 sites in five countries in Southeast Asia. We recorded patient demographics and assessed sleep quality and daytime drowsiness using visual analog scales...
2017: Psychology Research and Behavior Management
https://www.readbyqxmd.com/read/29114100/successful-treatment-of-severe-tardive-dyskinesia-with-valbenazine-including-a-patient-s-perspective
#17
Richard C Josiassen, Dawn M Filmyer, Jack Gillean, Syed Sikandar Shah, Tyler E Dietterich, Rita A Shaughnessy
BACKGROUND Tardive dyskinesia (TD) is a chronic involuntary movement disorder frequently induced by dopamine receptor blockers, particularly first-generation antipsychotics. Until recently, management of TD was restricted to lowering the dose of the current medication, switching to another medication, or using off-label treatments with insufficient evidence of efficacy. Valbenazine, a vesicular monoamine transporter-2 (VMAT2) inhibitor, became the first drug to be approved by the FDA specifically for the treatment of TD...
November 8, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/29073755/neutropenia-with-multiple-antipsychotics-including-dose-dependent-neutropenia-with-lurasidone
#18
Shabnam Sood
Antipsychotic-induced agranulocytosis is a significant side effect that is known to occur with most of the antipsychotic medications. It usually resolves once the medications are stopped and patients are able to be switched over to another antipsychotic medication. Lurasidone has not been reported to cause leukopenia and neutropenia. This case report is of a patient with a past history of risperidone induced-aganulocytosis developing dose related leukopenia and neutropenia with lurasidone.
November 30, 2017: Clinical Psychopharmacology and Neuroscience: the Official Scientific Journal of the Korean College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/29045304/effect-of-clozapine-vs-other-second-generation-antipsychotics-on-hospitalization-and-seclusion-a-retrospective-mirror-image-study-in-a-japanese-public-psychiatric-hospital
#19
Fuminari Misawa, Takefumi Suzuki, Yasuo Fujii
BACKGROUND: Clozapine has been regarded as the gold standard for patients with treatment-resistant schizophrenia, but a recent network meta-analysis has questioned its relative superiority over other second-generation antipsychotics (SGAs) such as olanzapine and risperidone. PURPOSE: We conducted a retrospective mirror-image study of clozapine vs other SGAs to evaluate real-world effectiveness of clozapine in terms of the duration of hospitalization and seclusion, both of which represent a critical outcome...
October 17, 2017: Journal of Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29018549/perceptions-and-knowledge-of-antipsychotics-among-mental-health-professionals-and-patients
#20
Lindah Cahling, Anders Berntsson, Gabriella Bröms, Lars Öhrmalm
Aims and method To assess the patients' most influential concerns regarding long-acting injectable antipsychotics (LAIs) and mental health professionals' preconceptions about these concerns. For both groups, to assess the level of knowledge about LAIs. This cross-sectional study used semi-structured interviews of patients with schizophrenia or schizoaffective disorder (n = 164), nurses (n = 43) and physicians (n = 20). Results The mental health professionals overestimated many of the patients' fears of LAIs, and the expressed fears exceeded the actual experiences of patients already on LAIs...
October 2017: BJPsych Bulletin
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"